Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,105,736
  • Shares Outstanding, K 98,307
  • Annual Sales, $ 673,000 K
  • Annual Income, $ -575,000 K
  • EBIT $ -535 M
  • EBITDA $ -504 M
  • 60-Month Beta 0.25
  • Price/Sales 3.06
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 46.64% (-8.73%)
  • Historical Volatility 55.93%
  • IV Percentile 11%
  • IV Rank 6.02%
  • IV High 187.31% on 12/26/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 15) 2.97 (13.62%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 72
  • Volume Avg (30-Day) 885
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 29,341
  • Open Int (30-Day) 22,577
  • Expected Range 18.81 to 24.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.50
  • Number of Estimates 9
  • High Estimate $-1.06
  • Low Estimate $-2.01
  • Prior Year $-1.57
  • Growth Rate Est. (year over year) +4.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.29 +20.45%
on 03/24/26
23.19 -5.00%
on 03/10/26
-0.99 (-4.30%)
since 03/02/26
3-Month
18.29 +20.45%
on 03/24/26
25.82 -14.68%
on 02/03/26
-1.57 (-6.65%)
since 01/02/26
52-Week
18.29 +20.45%
on 03/24/26
42.37 -48.01%
on 07/09/25
-13.34 (-37.72%)
since 04/02/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE)....

RARE : 22.04 (+2.89%)
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration...

RARE : 22.04 (+2.89%)
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx Lawsuit - RARE

NEW YORK , April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities...

RARE : 22.04 (+2.89%)
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).

RARE : 22.04 (+2.89%)
RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit

NEW YORK , March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August...

RARE : 22.04 (+2.89%)
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

NOVATO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug...

RARE : 22.04 (+2.89%)
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE

LOS ANGELES , March 30, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE)...

RARE : 22.04 (+2.89%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 30, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical...

RARE : 22.04 (+2.89%)
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options

RARE : 22.04 (+2.89%)
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ...

RARE : 22.04 (+2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 22.32
2nd Resistance Point 21.94
1st Resistance Point 21.68
Last Price 22.04
1st Support Level 21.04
2nd Support Level 20.66
3rd Support Level 20.40

See More

52-Week High 42.37
Fibonacci 61.8% 33.17
Fibonacci 50% 30.33
Fibonacci 38.2% 27.49
Last Price 22.04
52-Week Low 18.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.